Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer

Richard Zellars, Vered Stearns, Deborah Frassica, Fariba Asrari, Theodore Tsangaris, Lee Myers, Shirley DiPasquale, Julie R. Lange, Lisa K. Jacobs, Leisha A. Emens, Deborah K. Armstrong, John H. Fetting, Elizabeth Garrett-Mayer, Nancy E. Davidson, Antonio C. Wolff

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: Anthracyclines and concurrent whole-breast irradiation result in prohibitive cutaneous toxicity. We hypothesized that anthracycline-based chemotherapy and concurrent partial breast irradiation (PBI) is safe and conducted a single-arm feasibility trial testing this hypothesis with dose-dense doxorubicin and cyclophosphamide (ddAC). Patients and Methods: Women with T1-2, N0-1 breast cancer with ≥ 3 mm lumpectomy margins received PBI (40.5 Gy, 15 daily 2.7-Gy fractions) concurrently with the first two of four cycles of ddAC (60 and 600 mg/m2 of doxorubicin and cyclophosphamide, respectively, every 14 days with colony-stimulating support). Primary end points were local and systemic toxicity. Additional systemic therapy was given at the physician's discretion. Results: Twenty-seven patients enrolled between November 2004 and January 2007, but two patients did not receive protocol therapy (one found with additional local disease and one withdrew consent). Twenty-five women completed all planned PBI. Four (16%) of 25 did not complete all ddAC (febrile neutropenia [FN], n = 2; diverticulitis and neutropenia, n = 1; and social/economic reasons, n = 1). Four among the remaining 21 who completed all ddAC had a cycle delayed (FN, n = 1; acute respiratory illness, n = 1; foot blisters, n = 1; perianal dermatitis, n = 1). There was no grade 3 to 4 anemia or thrombocytopenia. Grade 3 nonhematologic toxicities (none grade 4) occurred in 28% (seven of 25) of patients (nausea/vomiting, n = 3; stomatitis, n = 2; contralateral breast abscess, n = 1; fatigue, n = 1; and cough/bronchospasms, n = 1). The observed rate of ≥ grade 2 skin toxicity was 0% (0 of 25; one-sided 95% CI, 0% to 11%). Conclusion: PBI with concurrent ddAC is feasible, and local/systemic toxicity is acceptable. Larger studies are warranted to assess long-term locoregional control and late toxicities.

Original languageEnglish (US)
Pages (from-to)2816-2822
Number of pages7
JournalJournal of Clinical Oncology
Volume27
Issue number17
DOIs
StatePublished - Jun 10 2009

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer'. Together they form a unique fingerprint.

Cite this